• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2019冠状病毒病死亡病例的症状负担与临床特征:一项快速系统综述及证据总结

Symptom burden and clinical profile of COVID-19 deaths: a rapid systematic review and evidence summary.

作者信息

Keeley Paul, Buchanan Deans, Carolan Clare, Pivodic Lara, Tavabie Simon, Noble Simon

机构信息

Palliative Care Team, Glasgow Royal Infirmary, Glasgow, UK

MVLS, University of Glasgow, Glasgow, UK.

出版信息

BMJ Support Palliat Care. 2020 Dec;10(4):381-384. doi: 10.1136/bmjspcare-2020-002368. Epub 2020 May 28.

DOI:10.1136/bmjspcare-2020-002368
PMID:32467101
Abstract

UNLABELLED

The spread of pandemic COVID-19 has created unprecedented need for information. The pandemic is the cause of significant mortality and with this the need for rapidly disseminated information for palliative care professionals regarding the prevalence of symptoms, their intensity, their resistance or susceptibility to symptom control and the mode of death for patients.

METHODS

We undertook a systematic review of published evidence for symptoms in patients with COVID-19 (with a specific emphasis on symptoms at end of life) and on modes of death. Inclusion: prospective or retrospective studies detailing symptom presence and/or cause or mode of death from COVID-19.

RESULTS

12 papers met the inclusion criteria and gave details of symptom burden: four of these specifically in the dying and two detailed the cause or mode of death. Cough, breathlessness, fatigue and myalgia are significant symptoms in people hospitalised with COVID-19. Dyspnoea is the most significant symptom in the dying. The mode of death was described in two papers and is predominantly through respiratory or heart failure.

CONCLUSIONS

There remains a dearth of information regarding symptom burden and mode of death to inform decisions regarding end-of-life care in patients dying with COVID-19. Rapid data gathering on the mode of death and the profile of symptoms in the dying and their prevalence and severity in areas where COVID-19 is prevalent will provide important intelligence for clinicians. This should be done urgently, within ethical norms and the practicalities of a public health, clinical and logistical emergency.

摘要

未标注

新冠大流行的传播引发了对信息前所未有的需求。这场大流行导致了大量死亡,因此需要迅速向姑息治疗专业人员传播有关症状的发生率、严重程度、对症状控制的抵抗或易感性以及患者死亡方式的信息。

方法

我们对已发表的关于新冠患者症状(特别强调临终时的症状)和死亡方式的证据进行了系统综述。纳入标准:详细描述新冠患者症状存在情况和/或死因或死亡方式的前瞻性或回顾性研究。

结果

12篇论文符合纳入标准,并给出了症状负担的详细信息:其中4篇专门针对临终患者,2篇详细说明了死因或死亡方式。咳嗽、呼吸困难、疲劳和肌痛是新冠住院患者的显著症状。呼吸困难是临终患者最显著的症状。两篇论文描述了死亡方式,主要是呼吸衰竭或心力衰竭。

结论

关于症状负担和死亡方式的信息仍然匮乏,无法为新冠临终患者的临终关怀决策提供依据。在新冠流行地区迅速收集关于死亡方式、临终患者症状特征及其发生率和严重程度的数据,将为临床医生提供重要信息。这应在伦理规范以及公共卫生、临床和后勤紧急情况的实际情况下紧急完成。

相似文献

1
Symptom burden and clinical profile of COVID-19 deaths: a rapid systematic review and evidence summary.2019冠状病毒病死亡病例的症状负担与临床特征:一项快速系统综述及证据总结
BMJ Support Palliat Care. 2020 Dec;10(4):381-384. doi: 10.1136/bmjspcare-2020-002368. Epub 2020 May 28.
2
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease.用于确定在基层医疗或医院门诊就诊的患者是否患有新冠病毒病的体征和症状。
Cochrane Database Syst Rev. 2020 Jul 7;7(7):CD013665. doi: 10.1002/14651858.CD013665.
3
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗或医院门诊环境中,出现症状和体征来确定患者是否患有 COVID-19。
Cochrane Database Syst Rev. 2021 Feb 23;2(2):CD013665. doi: 10.1002/14651858.CD013665.pub2.
4
Symptom Criteria for COVID-19 Testing of Heath Care Workers.医护人员 COVID-19 检测的症状标准。
Acad Emerg Med. 2020 Jun;27(6):469-474. doi: 10.1111/acem.14009. Epub 2020 Jun 8.
5
Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicentre) and outside Hubei (non-epicentre): a nationwide analysis of China.中国全国范围内的分析:湖北省(疫情中心)和湖北省外(非疫情中心)住院治疗的 COVID-19 患者的临床特征和结局。
Eur Respir J. 2020 Jun 4;55(6). doi: 10.1183/13993003.00562-2020. Print 2020 Jun.
6
COVID-19 and Hospital Palliative Care - A service evaluation exploring the symptoms and outcomes of 186 patients and the impact of the pandemic on specialist Hospital Palliative Care.COVID-19 和医院姑息治疗 - 一项服务评估,探讨了 186 名患者的症状和结果,以及大流行对专科医院姑息治疗的影响。
Palliat Med. 2020 Oct;34(9):1256-1262. doi: 10.1177/0269216320949786. Epub 2020 Aug 14.
7
Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic.与严重冠状病毒感染相关的精神和神经精神症状表现:一项系统综述和荟萃分析,并与新冠疫情进行比较
Lancet Psychiatry. 2020 Jul;7(7):611-627. doi: 10.1016/S2215-0366(20)30203-0. Epub 2020 May 18.
8
A Dual-Center Observational Review of Hospital-Based Palliative Care in Patients Dying With COVID-19.一项针对新冠病毒病临终患者的医院姑息治疗的双中心观察性综述
J Pain Symptom Manage. 2020 Aug;60(2):e75-e78. doi: 10.1016/j.jpainsymman.2020.04.031. Epub 2020 May 6.
9
An audit of end-of-life symptom control in patients with corona virus disease 2019 (COVID-19) dying in a hospital in the United Kingdom.对英国一家医院内死于 2019 冠状病毒病(COVID-19)的患者临终症状控制情况的审核。
Palliat Med. 2020 Oct;34(9):1249-1255. doi: 10.1177/0269216320947312. Epub 2020 Jul 31.
10
Interventions for palliative symptom control in COVID-19 patients.干预措施以控制 COVID-19 患者的姑息症状。
Cochrane Database Syst Rev. 2021 Aug 23;8(8):CD015061. doi: 10.1002/14651858.CD015061.

引用本文的文献

1
Hospital-based specialist palliative care involvement before and during the COVID-19 pandemic: secondary analysis of a regional retrospective decedent cohort study in Ottawa, Canada.新冠疫情之前及期间基于医院的专科姑息治疗参与情况:加拿大渥太华一项地区回顾性死亡队列研究的二次分析
BMJ Open. 2025 Mar 22;15(3):e091331. doi: 10.1136/bmjopen-2024-091331.
2
Description and Analysis of Research on Death and Dying during the COVID-19 Pandemic, Published in Nursing Journals Indexed in SCOPUS.对发表于被SCOPUS收录的护理期刊上的关于新冠疫情期间死亡与临终研究的描述与分析
Nurs Rep. 2024 Mar 22;14(2):655-674. doi: 10.3390/nursrep14020050.
3
COVID-19 and End of Life in a Quaternary Australian Hospital: Referral for Palliative Care Consultation.
澳大利亚一家四级医院的新冠疫情与临终关怀:姑息治疗会诊转诊
Palliat Med Rep. 2024 Jan 5;5(1):3-9. doi: 10.1089/pmr.2023.0069. eCollection 2024.
4
Epidemiological, clinical and laboratory profile of patients presenting with severe acute respiratory syndrome (SARS-CoV-2) in Ethiopia.在埃塞俄比亚,出现严重急性呼吸综合征(SARS-CoV-2)的患者的流行病学、临床和实验室特征。
PLoS One. 2023 Dec 1;18(12):e0295177. doi: 10.1371/journal.pone.0295177. eCollection 2023.
5
Barriers to and facilitators of advance care planning implementation for medical staff after the COVID-19 pandemic: an overview of reviews.COVID-19 大流行后医务人员实施预先医疗照护计划的障碍和促进因素:系统评价概述。
BMJ Open. 2023 Oct 10;13(10):e075969. doi: 10.1136/bmjopen-2023-075969.
6
Comorbidities, symptoms and end-of-life medication use in hospitalised decedents before and during the COVID-19 pandemic: a retrospective regional cohort study in Ottawa, Canada.在 COVID-19 大流行之前和期间住院死亡者的合并症、症状和临终药物使用:加拿大渥太华的回顾性区域队列研究。
BMJ Open. 2023 Sep 5;13(9):e075518. doi: 10.1136/bmjopen-2023-075518.
7
Adaptation and multicentre validation of a patient-centred outcome scale for people severely ill with COVID (IPOS-COV).适应 COVID 重病患者的以患者为中心的结局量表(IPOS-COV)的改编和多中心验证。
Health Qual Life Outcomes. 2023 Mar 24;21(1):29. doi: 10.1186/s12955-023-02102-4.
8
Evaluation of risk scores as predictors of mortality and hospital length of stay for older COVID-19 patients.评估风险评分作为老年COVID-19患者死亡率和住院时间预测指标的情况。
Aging Med (Milton). 2023 Jan 10;6(1):56-62. doi: 10.1002/agm2.12238. eCollection 2023 Mar.
9
Symptom Management and Support in Dying Patients with Cancer and Coronavirus Disease-19-A Register-Based Study.癌症和 2019 冠状病毒病-19 临终患者的症状管理和支持:一项基于登记的研究。
J Palliat Care. 2023 Jul;38(3):261-267. doi: 10.1177/08258597231157622. Epub 2023 Feb 15.
10
Non-Typical Clinical Presentation of COVID-19 Patients in Association with Disease Severity and Length of Hospital Stay.新型冠状病毒肺炎患者的非典型临床表现与疾病严重程度及住院时间的关系
J Pers Med. 2023 Jan 10;13(1):132. doi: 10.3390/jpm13010132.